POPULARITY
Categories
In 2010, Giovanna Podda, shared her terrifying story of repeated alien abductions since she was 4 years old with Mistero, and Italian conspiracy show. She lost her job, was ran out of town and largely disappeared after being discredited by some experts. However, she reappeared in 2025 on MBC's Mysterious TV Surprise in Japan, sharing the same story and incistant it was true.Merchandise: https://freetherabbits.myshopify.comBuy Me A Coffee: DonateFollow: Website | Instagram | X | FacebookWatch: YouTube | RumbleMusic: YouTube | Spotify | Apple MusicFilms: https://merkelfilms.comย Email: freetherabbitspodcast@gmail.comDistributed by: merkel.mediaOutro Music:Joel Thomas โ Psy-OpYouTube | Spotify | Apple Music
1-2๋ถ [๋ด์ค์ ์ธ๊ณ] 1. 3์ฐจ ์๋ฒ ๊ฐ์ ์ ๋ณธํ์ ์์ โฆ๊ตญํ ํ๋ฒ ๋์ 2. โ100๋์ค-20๋ง์ ์' ํ์ค๋ก 3. ์ง๊ฐ ์์น ๊ธฐ๋ ์๋ฌ๋ง์ ๊บพ์๋ค - MBC ํ์์ค ๊ธฐ์ (์ถ์ฐ) [์ด์ํ์ดํฅ] โ๊ณต์์ทจ์๋ชจ์' ์ถ๋ฒโฆ๊ณํํ ์ฐ๋ ค๋? - ๋๋ถ์ด๋ฏผ์ฃผ๋น ํ๋ฏผ์ ์์ (์ถ์ฐ)
1-2๋ถ [๋ด์ค์ ์ธ๊ณ] 1. ํธ๋ผํ, 15% ๊ด์ธ ๊ฐํ 2. ๊ฒฝ๊ธฐ์ง์ฌ ์ ํฉ๋, ๊น๋์ฐ ์ ๋ 3. ์ฅ๋ํ "ๆ๊ณต์์ทจ์ ๋ชจ์, ๋ฏธ์น ์ง" - ํ์์ค MBC ๊ธฐ์ (์ถ์ฐ) [์ด์ํ์ดํฅ1] ์ง์ D-100, ์กฐ๊ตญ-ํ๋ํ ๊ฑฐ์ทจ๋? - ์ฅ์ค์ ์ ์น์ ๋ฌธ๊ธฐ์ (์ถ์ฐ)
1-2๋ถ [๋ด์ค์ ์ธ๊ณ] 1. ์ฅ๋ํ, ์ฌ์ค์ ๅฐน์ด๊ฒ์ธ ์ ์ธ 2. ๋ฏผ์ฃผ 'ๅฐน ์ฌ๋ฉด ๊ธ์ง๋ฒ' ์ ์ ์ฒ๋ฆฌ 3. ์ ์๋ฏผ "๏งก ๊ณต์์ทจ์ ๋ชจ์, ๋ฏธ์ณค๋" - MBC ์ด์ ์ ๊ธฐ์ - ๊น์ข ํ ๊ตญ๋ฏผ์ํ ์ ์ต๊ณ ์์ - ๊ฐ์ฑํ ๋๋ถ์ด๋ฏผ์ฃผ๋น ๋ถ๋๋ณ์ธ (์ถ์ฐ)
1๋ถ [๋ด์ค์ ์ธ๊ณ] 1. ์ค์์ด ๋ด๋ 1์ฌ โ๋ฌด๊ธฐ์ง์ญ' 2. ๅฐน ๋ฌด๊ธฐ์ง์ญโฆ์ ์น๊ถ ๋ฐ์์ 3. ๆ "๋ง๊ตญ์ ๋ถ๋์ฐ ๊ณตํ๊ตญ ๊ทน๋ณตํด์ผ" - MBC ์ด์ ์ ๊ธฐ์ (์ถ์ฐ) 2๋ถ [์ด์๋๋ด] โ๋ด๋ ์ฐ๋๋จธ๋ฆฌ' ์ค์์ด 1์ฌ ์ ๊ณ - ๋๋ถ์ด๋ฏผ์ฃผ๋น ์ถ๋ฏธ์ ์์ - ์กฐ๊ตญํ์ ๋น ๋ฐ์์ ์์ (์ถ์ฐ)
1-2๋ถ [๋ด์ค์ ์ธ๊ณ] 1. ๋ํต๋ น ์ง์ง์จ 64%โฆ่ 46% vs ้ 23% 2. ์์ธ์์ฅ ์ ์์ค 40% vs ์ค์ธํ 36% 3. ์ ๋ถ ์ฆ์ ์ ์ฑ โฆ์์์ธต 68% '์ํ๋ค' - MBC ํ์์ค ๊ธฐ์ (์ถ์ฐ) [์ด์ํ์ดํฅ] ํฉ๋น-์์ฒญโฆ์ค ๋ฐฅ์ ์์ ๋? - ์ฅ์ค์ ๊ธฐ์ (์ถ์ฐ)
1-2๋ถ [๋ด์ค์ ์ธ๊ณ] 1. ๊ณ ์ฑ๊ตญ, '๊ฐ๋๋ ํ ๋ฌ ์ํน' ์ ๊ธฐ ๋ฐ์ ์ ๊ณ ์ 2. ๆ '๋ค์ฃผํ์ ๋์ถ ์ฐ์ฅ' ์ ๊ฒฉ 3. โ1๋ 8๊ฐ์' ๊น๊ฑดํฌ, ํญ์ ์ด์ ์ ์ ์ถ - MBC ์ด์ ์ ๊ธฐ์ (์ถ์ฐ) [์ด์ํ์ดํฅ] ๏งก ๋ํต๋ น, ๋ค์ฃผํ์์ ๋ ๊ฒฝ๊ณ - ์ด๊ด์ ๊ด์๋ค ๋ณต๋๋ฐฉ ๋ํ (์ถ์ฐ)
1-2๋ถ [๋ด์ค์ ์ธ๊ณ] 1. ๋จ์ ยท๋จ์ ์ด์๋ฏผ์ ์ง์ญ 7๋ - ์ ์ธ๊ท ๋ณํธ์ฌ (์ถ์ฐ) 2. ์ฅ๋ํ ๋ถ์ฐธ์ ๋ํต๋ น ์ค์ฐฌ ๋ฌด์ฐ 3. ๊ฐ๋๋ ํ ๋ฌ๋ฒ, ๊ณ ์ฑ๊ตญ ์ํฅ ๋ฐ์๋ - MBC ์ด์ ์ ๊ธฐ์ (์ถ์ฐ) [๊ฑฐ์นจ์์ดํ์ดํฅ] ์ด์๋ฏผ 1์ฌ ์ง์ญ 7๋ โฆ์ ์ ํ๊ฐ? - ์ ์ธ๊ท ๋ณํธ์ฌ - ์ฅ์ฑ์ฒ ๊ณต๋ก ์ผํฐ ์์ฅ (์ถ์ฐ)
1-2๋ถ [๋ด์ค์ ์ธ๊ณ] 1. ํฉ๋น ๊ฒฐ๊ตญ ๋ฌด์ฐโฆ์ ์ฒญ๋ ๋ฆฌ๋์ญ โํ๊ฒฉ' 2. ่ ๊ฐ๋๊ตฌ, '๋ํต๋ น ํฉ๋น ์ฐฌ์ฑ' SNS ๋ ผ๋ 3. ๊ตญํ ์์ธ์๋น, ๊ณ ์ฑ๊ตญ์ ํ๋น ๊ถ์ - MBC ํ์์ค ๊ธฐ์ (์ถ์ฐ) [์ด์ํ์ดํฅ1] ๋ํต๋ น, ๋ด์ผ ์ฌ์ผ ๋ํ ํ๋โฆ์ฃผ์ ๋ ผ์๋? - ์ด๊ท์ฐ ์ฒญ์๋ ํ๋ณด์ํต์์ (์ถ์ฐ)
Scolรกirรญ Phobalscoil Chorca Dhuibhne - d'รฉirigh thar bar leo i gCraabh Sclรฉip na hรireann i mBรC.
1-2๋ถ [๋ด์ค์ ์ธ๊ณ] 1. ํน๊ฒ ์ถ์ฒ ๋ ผ๋โฆโ๋ํต๋ น๊ป ์ฃ์กโ 2. ์นํ๊ณ ๊น์ข ํ ์ ๋ช โฆ๋ค์์ ๋ฐฐํ์ง? 3. ํ์ฑ์ ์ฅ๊ด, 3์ฑ ๋ด๋จ๋ค - MBC ํ์์ค ๊ธฐ์ (์ถ์ฐ) [์ด์ํ์ดํฅ1] ํน๊ฒ ์ถ์ฒ ๋ดํโฆ๋ฒ์ฌ์๋ ๋ชฐ๋๋? - ๋๋ถ์ด๋ฏผ์ฃผ๋น ๊น์ฉ๋ฏผ ์์ (์ถ์ฐ)
1-2๋ถ [๋ด์ค์ ์ธ๊ณ] 1. ๋ฏผ์ฃผยทํ์ ํฉ๋น ๋์ธ๋น ๋ฌธ๊ฑด ํ๋ฌธ 2. ์ฅ๋ํ '์ง ๊ฑธ๋ผ' ๋ฐ์ธ์ ์ค์ธํ๋ ๋ฐ๋ฐ 3. ์ฟ ํก ๋ก์ ์ค ๊ฒฝ์ฐฐ 2์ฐจ ์ถ์ - MBC ์ด์ ์ ๊ธฐ์ (์ถ์ฐ) [์ด์ํ์ดํฅ] โ๋ด๊ฐ ๋ฐ๋ก ์ค์ธํ ๋ํญ๋ง!โ - ์ ์์ค ์ฑ๋๊ตฌ์ฒญ์ฅ (์ถ์ฐ)
1-2๋ถ [๋ด์ค์ ์ธ๊ณ] 1. ์ธ์ฌ ๊ฒ์ฆ์ โ๋ค์ฃผํ' ๋ฌป๋๋ค 2. ์ค์์ฒญ ์ผ์ํยท๊ณต์์ฒญ์ โ์๊ตฌ๊ถ' ๊ฐ๋ฅ 2. ์ฅ๋ํ ์ฌ์ ์ยท์ฌํด ์ ๋น์ ํฌํ๋ก ๊ฒฐ์ 3. ์กฐ๊ตญ "๋น ์๋ค๊ณ ์์กด์ฌ๋ ์๋" - MBC ์ด์ ์ ๊ธฐ์ (์ถ์ฐ) [๊ฑฐ์นจ์์ดํ์ดํฅ] ํฉ๋น-์ ๋ช โฆ๋ดํ ํ์ฐ๋๋ ์ฌ์ผ - ์ ์ธ๊ท ๋ณํธ์ฌ - ์ฅ์ฑ์ฒ ๊ณต๋ก ์ผํฐ ์์ฅ (์ถ์ฐ)
Former government officials arrested, fuel levy reinstated, a cabinet reshuffle, MBC journalists suspended, new music production fees, and much more! Thanks for tuning in! Let us know what you think and what we can improve on by emailing us at info@rorshok.com. You can also contact us on Instagram @rorshok_malawi or Twitter @RorshokMalawiLike what you hear? Subscribe, share, and tell your buds.Former Government Officials Arrested For Financial Crimes: https://www.pijmalawi.org/show-story/pij-exclusive-billions-allegedly-secretly-paid-toReshuffles and Gomo's Town Hall Meetings by Emmanuel Luciano: https://mwnation.com/reshuffles-and-gomos-town-hall-meetings/ Check out our new t-shirts: https://rorshok.store/We want to get to know you! Please fill in this mini-survey: https://forms.gle/NV3h5jN13cRDp2r66Wanna avoid ads and help us financially? Follow the link: https://bit.ly/rorshok-donate
Bainteach le Ceolfhoireann Traidisiรบnta Mhuscraรญ - beidh siad ag seinm sa Cheolรกras Nรกisiรบnta i mBรC an Sathran beag seo.
1-2๋ถ [๋ด์ค์ ์ธ๊ณ] 1. ์ฒญ์๋ ๋ค์ฃผํ์ ์ฐธ๋ชจ๋ค ์ง ๋ด๋จ๋ค 2. ๋ฏผ์ฃผ๋น ์ต๊ณ ์์ ๋ ํฉ๋น ์ถฉ๋ 3. ็พ, ้ ๊ด์ธ ์ธ์ ๊ด๋ณด ๊ฒ์ฌ ํ์์ค - MBC ํ์์ค ๊ธฐ์ (์ถ์ฐ) [์ฃผ๊ฐ์ ์น๋ํ] ํฉ๋น๋ก ๋ดํโฆ๊ถ๋ ฅํฌ์ ๋ฒ์ง๋ - ์ด๋ํ ์๊ฐ (์ถ์ฐ)
1-2๋ถ [๋ด์ค์ ์ธ๊ณ] 1. ๋ํต๋ น SNS์ ๋ถ๋์ฐ ๊ฐ๊ฒฝ ๋ฉ์์ง 2. ๋ฏผ์ฃผ๋น ์ต๊ณ ์์ ํฉ๋น ๊ฐ๋ฑ ํ์ถ 3. ์ค์ธํ "์ฅ๋ํ ๋์ค์นด์ดํธ" ์ธ๊ธ - MBC ํ์์ค ๊ธฐ์ (์ถ์ฐ) [์ด์ํ์ดํฅ1] ๋ฏผ์ฃผ-ํ์ โํฉ๋น ๊ฐ๋ฑ' ์ฌ๋ถ์ถโฆ์ ์ฅ์? - ์ ์ฅ์ ์กฐ๊ตญํ์ ๋น ์์ (์ถ์ฐ)
In this beautifully hopeful episode, Wren, the creator of the Living Our Breast Lives Podcast, is joined by the incredible Metastatic Breast Cancer Thriver, Heather Jose, the MBC thriver living with triple positive metastatic breast cancer for 27 YEARS! Heather Jose is a long-term metastatic breast cancer thriver, advocate, and the host of the podcastย I'm Still Here: Lessons from Life with Metastatic Breast Cancer. Diagnosed at 26 and living with metastatic disease for over 25 years, Heather focuses on honest, grounded conversations about what it means to live fully โ not just survive โ alongside breast cancer. After her diagnosis, Heather went on to adopt a child, redefining what building a family can look like after metastatic breast cancer and showing that life doesn't stop at a diagnosis, it evolves. She has spent decades navigating treatment, motherhood, advocacy, and survivorship, all while helping others feel less alone.Listen to this episode as it breaks down:Who is Heather Jose? โ Meeting the woman behind the diagnosisHer MBC story โ Diagnosed in 1998, her subtype, and how she's still here decades laterThen vs. now โ What MBC treatment looked like then and how far it's comeStrength without the pressure โ The moments that carried her through and why the term "inspirational" comes with a heavy weight to itLiving with grief and joy โ Mourning the life imagined while fully living the one she hasMotherhood after MBC โ Infertility, adoption, and expanding her family against the oddsโI'm Still Hereโ โ Why Heather launched her podcast and who it's forLong-term survivorship โ What it really means and what she's still dreaming of for the future Living Our Breast Lives Information:Email: livingourbreastlivespodcast1@gmail.comInstagram: @livingourbreastlivesFounder: Wren MorrobelPersonal Instagram: @wren_morrPodcast Guest Speaker: Heather Jose's Information:Email: mail@heatherjose.comInstagram: @heatherbjoseFacebook: Heather JoseWebsite: www.heatherjose.comYouTube: I'm Still Here
1-2๋ถ [๋ด์ค์ ์ธ๊ณ] 1. โ์ฌ๋ฒ๋๋จ' ์์นํ 2์ฌ ์ง์ญํ ์ง์ 2. ์ ์ฒ์ง ์ฒซ ์์์์โฅ๊ตญํ ๋น์ ๊ฐ์ ์ํน 3. ๋ฏผ์ฃผ-ํ์ ํฉ๋น ๋๊ณ '๋ฐ์ฝ์ค' ๋ฑ์ฅ - MBC ์ด์ ์ ๊ธฐ์ (์ถ์ฐ) [์ด์ํ์ดํฅ] '์๋๊ถ 6๋งํธ'โฆ์ง๊ฐ ๋ถ์ ํด์๋ ๊น - ํ๋ฌธ๋ ๋ช ์ง๋ ๋ํ์ ์ค๋ฌดํฌ์๋ถ์ํ๊ณผ ๊ต์ (์ถ์ฐ)
January 28, 2026 - Learning the Korean language opens the doors into a completely new depth of understanding Korean culture, and perhaps a career you never imagined having. Join acclaimed media figuresย Tyler Raschย andย Nidhi Agrawalโfamiliar faces from major Korean broadcast networks including JTBC, KBS, and MBCโfor a reflection on their personal journeys living in Korea and learning Korean, and how those experiences led to their new venture. In this engaging conversation, Tyler and Nidhi will delve into how language can function as both a cultural bridge and a creative medium, and how Hangeul can travel beyond Korea through design, storytelling, and shared cultural moments in everyday settings. For more information, please visit the link below: https://www.koreasociety.org/arts-culture/2111-from-learning-to-creating
Did you know that as MBC patients get treated with multiple lines of ET, the percentage of patients who develop an ESR1 mutation increases? Credit available for this activity expires: 1/26/27 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/current-and-future-oral-serd-strategies-management-er-2026a100022b?ecd=bdc_podcast_libsyn_mscpedu
1-2๋ถ [๋ด์ค์ ์ธ๊ณ] 1. ํ๋ํ ์ ๋ช โฆ๊ตญ๋ฏผ์ํ ๋ดํ ๊ฒฉํ 2. ๅฐน ๊ด์ ๊ณจํ์ฐ์ต์ฅ, โ์ด์ ๊ณต์ฌ'๋ก ๊พธ๋ฉฐ 3. ์ ๋ถ, ์์ธยท์๋๊ถ์ 6๋งํธ ๊ณต๊ธ - MBC ์ด์ ์ ๊ธฐ์ (์ถ์ฐ) [์ด์ํ์ดํฅ] ์ฃผ๊ฐ๋ ๋ฐ์๋๋ฐโฆ์ค๋ฌผ๊ฒฝ์ ํด๋ฒ์? - ๊ตฌ์ค์ฒ ๊ฒฝ์ ๋ถ์ด๋ฆฌยท์ฌ์ ๊ฒฝ์ ๋ถ ์ฅ๊ด (์ ํ)
1-2๋ถ [๋ด์ค์ ์ธ๊ณ] 1. ๊น๊ฑดํฌ 1์ฌ ์ง์ญ 1๋ 8๊ฐ์ 2. ํธ๋ผํ ๊ด์ธ ์๋ฐ, ์ฟ ํก ๋๋ฌธ? 3. ๆ "๋ด๋ฐฐ์ฒ๋ผ โ์คํ์ธโ ๊ฑท์" - ๊น์ ํ ๋ณํธ์ฌ (์ถ์ฐ) - MBC ํ์์ค ๊ธฐ์ (์ถ์ฐ) [์ด์ํ์ดํฅ1] ํธ๋ผํ ๋๋ฐ ๊ด์ธ ์๋ฐโฆ๋์ฒ ๋ฐฉ์์? - ์ด๊ท์ฐ ์ฒญ์๋ ํ๋ณด์ํต์์ (์ถ์ฐ)
Featuring perspectives from Dr Angela DeMichele, Dr Komal Jhaveri, Dr Erica Mayer, Dr Hope S Rugo and Dr Seth Wander, including the following topics:ย Introduction (0:00) 1985 NCI Consensus Conference on Early Breast Cancer: Sir Richard Peto, FRS (2:01) Current Role of Genomic Assays in Treatment Decision-Making for Localized Hormone Receptor (HR)-Positive Breast Cancer โ Dr DeMichele (5:13) Case: A premenopausal woman in her mid 40s with an ER-positive, HER2-negative, node-negative infiltrating ductal carcinoma (IDC) after partial mastectomy/radiation therapy who enrolls in the prospective, observational FLEX study: MammaPrintยฎ low risk โ Laurie Matt-Amaral, MD, MPH (15:30) Case: A premenopausal woman in her mid 40s after modified radical mastectomy for T2N0 ER-positive, HER2-negative IDC with an Oncotypeย DXยฎย Recurrence Score (RSยฎ) of 19 โ Swati Vishwanathan, MD Case: A woman in her mid 60s with locally advanced (19 cm) ER-positive, HER2-low (IHC 1+) Stage IIIB mucinous carcinoma breast cancer and an RS of 18 โ Alan B Astrow, MD (22:40) Role of CDK4/6 Inhibitors and Other Novel Strategies in Therapy for HR-Positive, HER2-Negative Localized Breast Cancer โ Dr Jhaveri (30:18) Case: A woman in her mid 50s with ER-positive, HER2-negative Stage IIB, T2N1 IDC after neoadjuvant dose-dense AC-T, lumpectomy and adjuvant radiation therapy โ Eleonora Teplinsky, MD (42:14) Case: A woman in her mid 60s with ER-positive, HER2-negative breast cancer with a surgically removed solitary lung metastasis after 4 years of adjuvant letrozole โ Eric Fox, DO (46:32) Evolving Up-Front Treatment Paradigm for HR-Positive, HER2-Negative Metastatic Breast Cancer (mBC) โ Dr Rugo (49:45) Case: A woman in her early 80s with Type 2 diabetes, well controlled hypertension and recurrent ER-positive, HER2-negative mBC after 4 years of adjuvant letrozole โ Sunil Gandhi, MD (1:02:30) Clinical Utility of Agents Targeting the PI3K/AKT/mTOR Pathway for Patients with Progressive HR-Positive mBC โ Dr Mayer (1:06:37) Case: A woman in her late 60s with ER-positive, HER2-low (IHC 1+), PIK3CA-mutant mBC with disease progression after 2 years of adjuvant letrozole โ Laila Agrawal, MD (1:20:22) Case: A woman in her early 60s with ER-positive, HER2-low PIK3CA-mutant mBC and disease progression on first-line palbociclib/fulvestrant โ Dr Teplinsky (1:26:36) Results from the Global Phase III lidERA Breast Cancer Trial of Giredestrant versus Standard Endocrine Therapy as Adjuvant Treatment for ER-Positive, HER2-Negative Localized Breast Cancer (1:31:48) Current and Future Role of Oral Selective Estrogen Receptor Degraders for Progressive HR-Positive mBC โ Dr Wander (1:42:30) Case: A woman in her early 100s with locally advanced ER-positive, HER2-negative breast cancer with disease progression on letrozole, now with an ESR1 mutation โ Dr Astrow (1:57:51) CME information and select publications
1-2๋ถ [๋ด์ค์ ์ธ๊ณ] 0. ์ฝ์ค๋ฅ 1000 ๋ํ 1. ์ดํด์ฐฌ ์ ์ด๋ฆฌ ๋ณ์ธโฆ5์ผ๊ฐ ์ฌํ์ฅ 2. ์ดํํ ๋๋งโฆ์ฒญ์๋ ์ธ์ฌ ๊ฒ์ฆ ๋ ผ๋ 3. ๋ฏผ์ฃผ-ํ์ ํฉ๋น ์ ์ ์ฌ์ง - MBC ํ์์ค ๊ธฐ์ (์ถ์ฐ) [์ด์ํ์ดํฅ1] ๋ฏผ์ฃผ-ํ์ ํฉ๋น ๋ ๊นโฆํจ๊ณผ๋? - ๋๋ถ์ด๋ฏผ์ฃผ๋น ๊น์ฉ๋ฏผ ์์ (์ถ์ฐ)
1-2๋ถ [๋ด์ค์ ์ธ๊ณ] 1. ๊ตญํ์ ์ดํํ ์ฒญ๋ฌธํโฆ์ถ๊ฐ ์ํน ๋๋ง 2. ๋ฏผ์ฃผ-ํ์ ํฉ๋น ์ ์ ํํญํ 3. ็พ ํฌ์์ฌ๋ค "้ ์ ๋ถ๊ฐ ์ฟ ํก ์ฐจ๋ณ" - MBC ์ด์ ์ ๊ธฐ์ (์ถ์ฐ) [์ด์ํ์ดํฅ] โํฉ๋น ์ ์' ํํญํโฆ์ ์ง๊ธ? - ๋ฐ์ํ ๋๋ถ์ด๋ฏผ์ฃผ๋น ์์๋๋ณ์ธ (์ถ์ฐ)
In this podcast, experts William J. Gradishar, MD, FASCO, FACP; Stephanie L. Graff, MD, FACP, FASCO; and Cynthia X. Ma, MD, PhD; discuss current and emerging therapeutic options, including next-generation endocrine therapies, to target the estrogen receptor signaling pathway for the treatment of hormone receptorโpositive/HER2-negative (HR+/HER2โ) metastatic breast cancer (MBC).
1-2๋ถ [๋ด์ค์ ์ธ๊ณ] 0. ์ฝ์คํผ 5000 ์ ์ญ์ฌ ์ผ๋ค 1. ์ ์ฒญ๋, ๋ฏผ์ฃผ๋น-์กฐ๊ตญ๋น ํฉ๋น ์ ์ 2. ์ด์๋ฏผยท๋ฐ์ฑ์ฌ๋ โ์คํ' ์ฒ ํด ๋ง๋? 3. ๊น๋ณ๊ธฐ ๋ฐฐ์ฐ์ ๊ฒฝ์ฐฐ ํผ์์ ์ถ์ - MBC ์ด์ ์ ๊ธฐ์ (์ถ์ฐ) [๊ฑฐ์นจ์์ดํ์ดํฅ] ์ ์ฒญ๋, ํ์ ๋น์ ํฉ๋น ์ ์โฆ์ ์น๊ถ ํ์ฅ์? - ์ ์ธ๊ท ๋ณํธ์ฌ - ์ฅ์ฑ์ฒ ๊ณต๋ก ์ผํฐ ์์ฅ (์ถ์ฐ)
1-2๋ถ [๋ด์ค์ ์ธ๊ณ] [๋ฏธ๋์ธํฐ๋ทฐ] 1. โ12.3์ ๋ด๋โโฆํ๋์, ์ง์ญ 23๋ - ๊น์ ํ ๋ณํธ์ฌ (์ ํ) 2. ์ด์ฌ๋ช ๋ํต๋ น ์ ๋ ๊ธฐ์ํ๊ฒฌ 3. ํ์คํ "ๅฐน, ์ ์ฒ์ง ๋ชฐํ๋ก ํ๋ณด ๋๋ค" - MBC ํ์์ค ๊ธฐ์ (์ถ์ฐ) [์ฃผ๊ฐ์ ์น๋ํ] ๊ฒ์ฐฐยท์ดํํยท์ง๊ฐโฆ์ญ๋ ์ต์ฅ ๋ํต๋ น ๊ธฐ์ํ๊ฒฌ - ์ด๋ํ ์๊ฐ (์ถ์ฐ)
High-quality behavioral healthcare scales only when outcomes, engagement, and coordination are designed into the system from day one. In this episode, Colleen Marshall, Chief Clinical Officer at Two Chairs, discusses how integrating therapy and psychiatry under one roof improves outcomes, reduces drop-off, and removes friction for patients. She explains measurement-based care (MBC), why real-time feedback in sessions drives better results, and how clinician training unlocks adoption. Colleen explores patient engagement, including why rapid access and strong matching matter and how coordinated care prevents conflicting treatment plans. She also breaks down value-based care in behavioral health, sharing how outcomes and retention can anchor shared-risk partnerships with payers. Finally, Colleen looks ahead to the future of behavioral health, including the responsible use of AI to support clinicians while maintaining ethical and effective care. Tune in and learn how outcomes, engagement, and coordination can redefine success in behavioral healthcare! Resources: Connect with and follow Colleen Marshall on LinkedIn. Follow Two Chairs on LinkedIn and visit their website.
1-2๋ถ [๋ด์ค์ ์ธ๊ณ] 1. ๊น๋ณ๊ธฐ, ์ฌ์ฌ ํฌ๊ธฐ ์ด์ด ํ๋น๊ณ ์ ์ถ 2. '์ดํํ ์ฒญ๋ฌธํ' ํ๋ณด ์์ด ๊ณต๋ฐฉ๋ง 3. ํ๋ํ โ์ก๊ตฌโโฆ์ฅ๋ํ์ ์นจ๋ฌต - MBC ํ์์ค ๊ธฐ์ (์ถ์ฐ) [์ด์ํ์ดํฅ1] โ๊ฒ์ฐฐ๊ฐํ ์ ๋ถ์, ์ ๋ฉด ์์ ํด์ผโ - ์ ์ฅ์ ์กฐ๊ตญํ์ ๋น ์์ (์ถ์ฐ)
1-2๋ถ [๋ด์ค์ ์ธ๊ณ] 1. ๋ฒ์, ๅฐน ์ฒดํฌ ๋ฐฉํด ํ์ ๋ฑ '์ง์ญ 5๋ ' ์ ๊ณ 2. ๏งก๋ํต๋ น-์ฌ์ผ ์ง๋๋ถ, ๊ตญํ ๋ถ์ฐธ ์ ์ค์ฐฌ 3. ๊น๊ฒฝยท๊ฐ์ ์ฐยทๅ๋ณด์ข๊ด, ๋ชจ๋ ์ง์ ์๊ฐ๋ ค - MBC ์ด์ ์ ๊ธฐ์ (์ถ์ฐ) [์ด์ํ์ดํฅ1] ๋ฒ์ "ๅฐน, ๊ฒฝํธ์ฒ ์ฌ์ค์ ์ฌ๋ณํ" - ๋๋ถ์ด๋ฏผ์ฃผ๋น ์ค๊ฑด์ ์์ (์ถ์ฐ)
1-2๋ถ [๋ด์ค์ ์ธ๊ณ] 1. ๋ด์ผ ๅฐน โ์ฒดํฌ๋ฐฉํด' ์ ๊ณ โฆ2์ ์์ค๊ณ 2. ์ฅ๋ํ, ํ๋ํ ์ ๋ช ๊ฒฐ์ ์ฐ๊ธฐ 3. ๊ฒฝ์ฐฐ, ๊น๊ฒฝ ์ฌ์ํโฆโ์ฌ๋ ค ๋ผ์ณ ์ฃ์กโ - MBC ์ด์ ์ ๊ธฐ์ (์ถ์ฐ) [๊ฑฐ์นจ์์ดํ์ดํฅ] ํ๋ํ ์ ๋ช โ๋ณด๋ฅ'โฆๅผต ์๋ด๋? - ์ ์ธ๊ท ๋ณํธ์ฌ - ์ฅ์ฑ์ฒ ๊ณต๋ก ์ผํฐ ์์ฅ (์ถ์ฐ)
Featuring perspectives from Prof Giuseppe Curigliano, Prof Nadia Harbeck, Dr Ian E Krop, Dr Nancy U Lin and Dr Joyce O'Shaughnessy, including the following topics:ย Introduction (0:00) Considerations in the Care of Patients with Localized HER2-Positive Breast Cancer โ Prof Harbeck (1:39) Case: A woman in her mid 50s presents with locally advanced ER-positive, HER2-positive breast cancer โ Alan B Astrow, MD (12:52) Case: A woman in her mid 40s with ER-positive, HER2-positive Stage II breast cancer s/p neoadjuvant TCHP with residual disease receives adjuvant T-DM1 but discontinues due to neuropathy โ Laila Agrawal, MD (20:02) Previously Untreated HER2-Positive Metastatic Breast Cancer (mBC) โ Prof Curigliano (25:10) Case: A woman in her early 80s presents with de novo metastatic (bone-only) ER-positive, HER2-positive breast cancer โ Zanetta S Lamar, MD (35:03) Optimal Management of Brain Metastases in Patients with HER2-Positive Breast Cancer โ Dr Lin (46:20) Case: A woman in her early 60s with ER-positive, HER2-positive breast cancer develops a cerebellar metastasis while receiving adjuvant anastrozole after prior anti-HER2 therapy โ Justin Favaro, MD, PhD (59:41) Case: A woman in her early 40s with ER-negative, HER2-positive mBC develops a headache shortly after neoadjuvant TCHP, surgery and postneoadjuvant T-DM1 and is found to have an isolated 4-cm brain metastasis โ Dr Agrawal (1:05:36) Selection and Sequencing of Therapy for Relapsed/Refractory HER2-Positive mBC in the Absence of CNS Involvement โ Dr Krop (1:12:00) Case: A woman in her early 40s with ER-positive, HER2-positive mBC receives THP (docetaxel/trastuzumab/pertuzumab) and maintenance tucatinib with trastuzumab/pertuzumab on a clinical trial and now has disease progression โ Yanjun Ma, MD, PhD (1:23:04) Tolerability Considerations with HER2-Targeted Therapies โ Dr O'Shaughnessy (1:29:32) Case: A woman in her mid 60s presents with localized ER-negative, HER2-positive infiltrating ductal carcinoma โ Erik Rupard, MD (1:46:06) Case: A woman in her early 70s with recurrent ER-positive, HER2-positive mBC receives trastuzumab deruxtecan (T-DXd) and has concerning pulmonary symptoms but without findings on diagnostic imaging โ Kimberly Ku, MD Case: A woman in her mid 40s with ER-positive, HER2-positive breast cancer metastatic to the brain and lung who received multiple prior treatments responds to T-DXd but develops Grade 1 interstitial lung disease โ Richard Zelkowitz, MD (1:49:49) CME information and select publications
1-2๋ถ [๋ด์ค์ ์ธ๊ณ] 1. ์ค์์ด ์ฌํ ๊ตฌํ 2. ๊ตญํ ์ค๋ฆฌ์, ํ๋ํ ๊ธฐ์ต ์ ๋ช 3. ๊น๊ฒฝ โ1์ต ์ค๋, ๊ฐ์ ์ฐ ํจ๊ป ์์๋คโ - MBC ํ์์ค ๊ธฐ์ (์ถ์ฐ) [์ด์ํ์ดํฅ1] ๋ง ๋ง์ ๊ฒ์ฐฐ๊ฐํโฆ์ฒญ์๋ ์ ์ฅ์? - ์ด๊ท์ฐ ์ฒญ์๋ ํ๋ณด์ํต์์ (์ถ์ฐ)
1-2๋ถ [๋ด์ค์ ์ธ๊ณ] 1. ๊น๊ฒฝ ๊ท๊ตญ, ์๋ฒฝ๊น์ง ๊ฒฝ์ฐฐ ์กฐ์ฌ 2. ๊น๋ณ๊ธฐ ์ ์๋ด๋ํ ์ค๋ฆฌ์ฌํ์ ์ถ์ 3. ์ ์๋ด๋ํ์ ํ๋ณ๋ ์์ ์ ์ถ - ํ์์ค MBC ๊ธฐ์ (์ถ์ฐ) [์ด์ํ์ดํฅ1] ๊ณต์์ฒญยท์ค์์ฒญ ์ด์์ ๊ณต๊ฐโฆ๊ฐํ ๋ง๋? - ๊น์ฉ๋ฏผ ๋๋ถ์ด๋ฏผ์ฃผ๋น ์์ (์ถ์ฐ)
1-2๋ถ [๋ด์ค์ ์ธ๊ณ] 1. ๅฐน ๋ด๋ํ์ ๊ฒฐ์ฌ๊ณตํ 2. ์ดํํ โ๋ถ์ ํฉ' 47%, โ์ ํฉ' 16% 3. ๊น๊ฒฝ, '๊ฐ์ ์ฐ 1์ต' ํ์ ์ธ์ ์์ ์ ์ ์ถ - ์ด์ ์ MBC ๊ธฐ์ (์ถ์ฐ) [์ด์ํ์ดํฅ] ์ฌํ? ๋ฌด๊ธฐ์ง์ญ? ํน๊ฒ ๊ตฌํ ์ ๋ง์ - ๋ฐ์์ ์กฐ๊ตญํ์ ๋น ์์ (์ถ์ฐ)
Featuring perspectives from Dr Javier Cortรฉs, Dr Rita Nanda, Prof Peter Schmid and Dr Priyanka Sharma, including the following topics:ย Introduction (0:00) Case: A woman in her early 80s with multiple comorbidities and triple-negative breast cancer (TNBC) develops bone-only metastases 4 months after declining capecitabine for post-neoadjuvant residual disease โ Justin Favaro, MD, PhD (1:50) Case: A woman in her mid 70s with ER-negative, HER2-low (IHC 1+), PIK3CA-mutated, PD-L1-positive metastatic breast cancer (mBC) after receiving 3 cycles of neoadjuvant paclitaxel/carboplatin/pembrolizumab, which was discontinued โ Alan Astrow, MD (6:47) Previously Untreated Metastatic TNBC (mTNBC) โ Prof Schmid (10:47) ย Case: A woman in her early 80s with multiregimen-recurrent ER-positive, HER2-low (IHC 1+) ESR1-mutant mBC receives sacituzumab govitecan โ Jennifer Yannucci, MD (27:19) Case: The role of datopotamab deruxtecan (Dato-DXd) for patients with ER-positive, HER2-low mBC who experienced disease progression on prior trastuzumab deruxtecan (T-DXd) โ Ranju Gupta, MD;ย Case: A woman in her late 70s with bilateral recurrence in the lungs of ER-negative, HER2-low (IHC 1+) breast cancer (PD-L1 TPS 20%) receives Dato-DXd with durvalumab on protocol โ Yanjun Ma, MD, PhD (31:35) Integrating Antibody-Drug Conjugates (ADCs) into the Management of Endocrine-Resistant Hormone Receptor-Positive mBC โ Dr Sharma (36:31) Case: A woman in her early 70s with recurrent ER-negative, HER2-low (IHC 2+) mBC receives sacituzumab govitecan and achieves complete remission โ Dr Gupta;ย Case: Management of neutropenia associated with sacituzumab govitecan โ Gigi Chen, MD (50:30) Case: A woman in her late 60s with recurrent ER-negative, HER2-low (IHC 1+) mBC (HER2 V69L mutation) receives T-DXd and achieves a complete response but develops Grade 1 interstitial lung disease โ Dr Gupta;ย Case: Management of T-DXd-related side effects โ Laila Agrawal, MD (54:10) Selection and Sequencing of Therapy for Relapsed/Refractory mTNBC โ Dr Nanda (58:59) Case: A woman in her early 40s with multiregimen-recurrent ER-positive, HER2-low mBC who has experienced severe nausea with past treatments is about to initiate T-DXd โ Atif M Hussein, MD, MMM (1:12:40) Tolerability and Other Practical Considerations with ADCs and Other Cytotoxic Agents for mBC โ Dr Cortรฉs (1:18:10) CME information and select publications
1-2๋ถ [๋ด์ค์ ์ธ๊ณ] 1. โ์ฅ๋ํ ์์ ์' ๋๊ณ ์ฌ์ง 2. ๊น๋ณ๊ธฐ, ์ง๊ณํ์ ์ฐ๊ธฐ ์์ฒญโฆ์ค๋ฆฌ์ "์์ ๋๋ก" 3. ์๋ฐฉ์ธ ๊น์ฑํ "์ฐ์ดยท์ ํํฐ ์์ด" - ์ด์ ์ MBC ๊ธฐ์ (์ถ์ฐ) [๊ฑฐ์นจ์์ดํ์ดํฅ] ๊ณต์ฒ ์ํน-์นํ๊ณ ์ถ์ถโฆํผ๋์ ์ฌ์ผ - ์ ์ธ๊ท ๋ณํธ์ฌ - ์ฅ์ฑ์ฒ ๊ณต๋ก ์ผํฐ ์์ฅ (์ถ์ฐ)
1-2๋ถ [๋ด์ค์ ์ธ๊ณ] 1. ์ด ๋ํต๋ น, ์ค๊ตญ ํ์ง์ ๊ธฐ์ ๊ฐ๋ดํ 2. ์ฅ๋ํ โ์์ ์' ๋ฐํโฆ๋น์๊ณ์ ์ฒซ ์ฌ๊ณผ 3. ๊น๋ณ๊ธฐ ๋ฐฐ์ฐ์ '๋ฒ์นด ์ฌ์ฉ' ์ถ๊ฐ ์ํน ์ ๊ธฐ - ํ์์ค MBC ๊ธฐ์ (์ถ์ฐ) [์ฃผ๊ฐ์ ์น๋ํ] ์ปค์ง๋ ๊น๋ณ๊ธฐ ํ๋น ์๊ตฌ - ์ด๋ํ ์๊ฐ (์ถ์ฐ)
1-2๋ถ [๋ด์ค์ ์ธ๊ณ] 1. ๆ๋ํต๋ น, ์ค๋ ์์งํ๊ณผ ์ ์ํ๋ด 2. ๊ตญํ ์ค๊ตฌ์์ "์ดํํ, ๊ตฌ์์์ ๊ฐ์ง" 3. ็พ ๋ง๋๋ก ์ถ์ถโฆ์ธ๊ณ ๊ณณ๊ณณ ๋ฐ๋ฏธ ์์ - ํ์์ค MBC ๊ธฐ์ (์ถ์ฐ) [์ด์ํ์ดํฅ1] ์ดํํ, ์ฒญ๋ฌธํ ๋ฌธํฑ ๋์๊น? - ์ ์ฅ์ ์กฐ๊ตญํ์ ๋น ์์์ต๊ณ ์์ (์ถ์ฐ)
1-2๋ถ [๋ด์ค์ ์ธ๊ณ] 1. ๋ฏผ์ฃผ, ํ๋นํ ๊ฐ์ ์ฐ ์ ๋ช ๊ฒฐ์ 2. ์ด์ฌ๋ช ๋ํต๋ น ๊ตญ์ ์ง์ง์จ 63% 3. '๊ฐ์ง ์ํน' ์ดํํโฆ์ง๊ถ๋จ์ฉ ํ์ ๋ฑ ๊ณ ๋ฐ - ์ด์ ์ MBC ๊ธฐ์ (์ถ์ฐ) [์ด์ํ์ดํฅ] โ๊น๋ณ๊ธฐ-๊ฐ์ ์ฐ ์ํนโโฆ่ ์ ์ฌ ๋ํ๊ตฌ๋? - ๋ฐํ๊ทผ ๋๋ถ์ด๋ฏผ์ฃผ๋น ์์ (์ถ์ฐ)
1-2๋ถ [๋ด์ค์ ์ธ๊ณ] 1. ํ๋ํ, ๋น๋ฌด๊ฐ์ฌ ๊ฒฐ๊ณผ์ "๋๋ช ์ด์ธ" 2. ๊ฒฝ์ฐฐ โ๊ฐ์ ์ฐ 1์ต ์์' ์์ฌ ์ฐฉ์ 3. ๊น๋ณ๊ธฐ ๊ฐ์ง ์ํน 10๊ฑด ๊ณต๊ณต๋ฒ์ฃ์์ฌ๋๋ก - ํ์์ค MBC ๊ธฐ์ (์ถ์ฐ) [์ด์ํ์ดํฅ1] ๊ฒฝ์ ์ฌ๋ นํ์ ์ดํํ, ๋ํต๋ น์ ์๋ด๋? - ์ด๊ท์ฐ ์ฒญ์๋ ํ๋ณด์ํต์์ (์ถ์ฐ)
1-2๋ถ [๋ด์ค์ ์ธ๊ณ] 1. ์ดํํ ๊ธฐํ์์ฐ์ฒ ์ฅ๊ด ํ๋ณด์...๊ตญ๋ฏผ์ํ '์ ๋ช ' 2. ๊น๊ฑดํฌ ํน๊ฒ, ์์ฌ ๊ฒฐ๊ณผ ๋ฐํ 3. ๆ๋ํต๋ น ์ฒญ์๋ ์ฒซ ์ถ๊ทผ - ํ์์ค MBC ๊ธฐ์ (์ถ์ฐ) [์ด์ํ์ดํฅ1] ๊น๊ฑดํฌ ํน๊ฒ ๋ง๋ฌด๋ฆฌโฆ๋จ์ ์ํน์? - ๊น์ฉ๋ฏผ ๋๋ถ์ด๋ฏผ์ฃผ๋น ์์ (์ถ์ฐ)
1-2๋ถ [๋ด์ค์ ์ธ๊ณ] 1. ์ด์ ์ ์ ๋ถ ํจ์ฑโฆ์ฟ ํก โ์ ํ์กฐ์ฌ' ๋ ผ๋ 2. ๅฐน ์ฒซ ๊ตฌํ ์ง์ญ 10๋ "์ค๋๋ฒ์ฃ ์ฑ ์" 3. ๊น๋ณ๊ธฐ, ๊ณ์๋๋ ์ํน ํญ๋ก...๋ด์ฉ์? - ์ด์ ์ MBC ๊ธฐ์ (์ถ์ฐ) [์ด์ํ์ดํฅ] ํน๋ณ์กฐ์ฌ๊ตญ ํ์งโฆ๊ฐ์ฌ๊ตญ ๊ฐํ ๋ฐฉ์์ - ๊น์ธํ ์ ๊ฐ์ฌ์์ฅ ๊ถํ๋ํ (์ถ์ฐ)
1-2๋ถ [๋ด์ค์ ์ธ๊ณ] 1. 3์ฒ์ชฝ ํต์ผ๊ต ๋ด๋ถ๋ฌธ๊ฑด์ ๋๋ฌ๋ ๋ก๋น ์ ํฉ 2. ๊น๋ณ๊ธฐ, โ์๋ฐ๊ถ' ์ํน ์ด์ด ๊ฐ์กฑ ์์ ๋ ผ๋ 3. '์ค๊ณ์' ๋ ธ์์์ ๊ณ์ ์คํจ ์์ต ๊ณํ - ์ด์ ์ MBC ๊ธฐ์ (์ถ์ฐ) [๊ฑฐ์นจ์์ดํ์ดํฅ] ํ๋ํ-์ฅ๋ํ, ํํดํ ์ ์์๊น? - ์ ์ธ๊ท ๋ณํธ์ฌ - ์ฅ์ฑ์ฒ ๊ณต๋ก ์ผํฐ ์์ฅ (์ถ์ฐ)
1-2๋ถ [๋ด์ค์ ์ธ๊ณ] 1. 'ํ์ยท์กฐ์์ ๋ณด ์ ํต ๊ธ์ง' ๊ตญํ ๋ณธํ์ ํต๊ณผ 2. ๊น์ฉํยท์ฌ์ธํ ์ถ๊ฐ ๊ตฌ์โฆ์ฆ๊ฑฐ์ธ๋ฉธ ์ฐ๋ ค 3. ๊น๋ณ๊ธฐ, ํธํ ์๋ฐ๊ถ ์ด์ด '๊ฐ์กฑ ์์ โ ์ํน - ํ์์ค MBC ๊ธฐ์ (์ถ์ฐ) [์ด์ํ์ดํฅ1] ํต์ผ๊ต ํน๊ฒ, ์ถ์ฒ๊ถ ๋๊ณ ํ๊ฒจ๋ฃจ๊ธฐ - ์ด๋ํ ์๊ฐ (์ถ์ฐ)
Featuring perspectives from Dr Lisa A Carey and Dr Rita Nanda, including the following topics:ย Overview: Molecular basis of antibody-drug conjugate (ADC) toxicities โ Sequencing of ADCs and mechanisms of resistance (0:00) Case: A woman in her late 60s with localized triple-negative breast cancer develops myocarditis during neoadjuvant therapy with chemotherapy/pembrolizumab โ Richard Zelkowitz, MD (8:22) Case: A woman in her mid 70s with recurrent ER-negative, HER2-low, PD-L1-positive metastatic breast cancer (mBC) who experiences disease progression on nab paclitaxel/atezolizumab responds to sacituzumab govitecan โ Ranju Gupta, MD (26:43) Case: A woman in her early 80s with recurrent ER-positive, HER2-low (IHC 1+) mBC experiences disease progression on trastuzumab deruxtecan (T-DXd), then receives datopotamab deruxtecan and develops pulmonary symptoms โ Laila Agrawal, MD (32:11) Data Review: T-DXd (37:51) Case: A woman in her early 70s with recurrent ER-positive, HER2-low (IHC 1+) mBC, including bladder metastases, experiences disease progression after palbociclib/letrozole, then capivasertib/fulvestrant, then nab paclitaxel โ Justin Favaro, MD, PhD (44:02) Case: A woman in her late 70s with ER-positive, HER2-low mBC who experiences disease progression after 1 year of ribociclib/letrozole receives sacituzumab govitecan โ Erik Rupard, MD (55:19) CME information and select publications
In this educational, refreshing, and beautifully hopeful episode, Wren, the creator of the Living Our Breast Lives Podcast, is joined by the incredible Metastatic Breast Cancer Thriver, Carolyn Leigh, the President of North Star Cancer Advocacy.In 2018, she was the third member of her family to be diagnosed with metastatic breast cancer, including her mother and uncle. After her metastatic diagnosis, she spent years studying the latest scientific understandings about the immune system and immunotherapies for cancer before launching North Star Cancer Advocacy in 2022 with the aim of providing information to the community and advocating for vast increases in NIH funding. The North Star Board of Directors and the MBC community recently raised $100k to further the research of combining Natural Killer cells (immune system cells) and one of the most promising breast cancer drugs in preclinical development, ErSO-TFPy.In this episode, join me as Carolyn breaks down:ย - How the inspirational Judy Perkins and TILs therapy reshaped her belief in what's possible- The moment she decided to found North Star- A simple breakdown of MHC I expression and why some immunotherapies succeed while others don't- A crash course in how immunotherapy actually works inside the body- Her mission to raise six figures for immunotherapy-driven clinical trials โ and what real success would look like - How and where to access immunotherapy clinical trials- A raw conversation about allyship, momentum, and why the MBC movement can't depend solely on those living with the diseaseCarolyn isn't just an MBC advocateโฆ she's a brilliant mind, a fierce researcher, the president of the North Star Cancer Research Foundation, and a woman determined to change the future of metastatic breast cancer!Living Our Breast Lives Information:Email: livingourbreastlivespodcast1@gmail.comInstagram: @livingourbreastlivesFounder: Wren MorrobelPersonal Instagram: @wren_morrPodcast Guest Speaker: Carolyn Leigh's Information:Email: NorthStarCancerAdvocacy@yahoo.comInstagram: @north.star.cancer.advocacy@north.star.cancer.researchFacebook: North Star Cancer Research FoundationWebsite: NorthStarCancerResearch.orgCRI Clinical Trial Finder:https://cri.careboxhealth.com/en-US/
Send us a textToday's episode tackles a topic that is often misunderstood, palliative care. Many people hear the term and immediately think of end-of-life care but that's not what palliative care is. In reality, it's about improving quality of life, managing symptoms, and helping you live as fully and comfortably as possible, no matter where you are in your metastatic breast cancer (MBC) treatment.We're joined by Dr. Jones, a palliative care physician who has worked closely with people living with MBC. He brings not only medical expertise, but also deep compassion and insight into the emotional and physical needs of our community.In this conversation, we explore:What palliative care truly meansHow to access palliative care servicesWhy integrating palliative care early can make such a meaningful differenceWhether you're newly diagnosed or have been living with MBC for many years, this episode offers clarity, reassurance, and practical information to support you on your journey.Visit OurMBCLife.org for episode notes.